Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in high-risk melanoma patients

Given its ability to induce both humoral and cellular immune responses, NY-ESO-1 has been considered a suitable antigen for a cancer vaccine. Despite promising results from early-phase clinical studies in melanoma patients, NY-ESO-1 vaccine immunotherapy has not been widely investigated in larger tr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Immunol Res
Main Authors: Pavlick, Anna, Blazquez, Ana Belen, Meseck, Marcia, Lattanzi, Michael, Ott, Patrick A., Marron, Thomas U, Holman, Rose Marie, Mandeli, John, Salazar, Andres, McClain, Christopher, Gimenez, Gustavo, Balan, Sreekumar, Gnjatic, Sacha, Sabado, Rachel Lubong, Bhardwaj, Nina
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6946846/
https://ncbi.nlm.nih.gov/pubmed/31699709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-19-0545
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados